Advertisement

Fettgewebsdysfunktion

  • A. Schäffler
  • C. Bollheimer
  • R. Büttner
  • C. Girlich
  • C. Aslanidis
  • W. Dietmaier
  • M. Bala
  • V. Guralnik
  • T. Karrasch
  • S. Wurm
Chapter

Zusammenfassung

Ein erhöhtes Körpergewicht (Übergewicht, erfasst durch die Bestimmung des BMI) geht klinisch in der überwiegenden Mehrzahl der Fälle einher mit einer relativen Zunahme des Anteils der Körperfettmasse am Gesamtkörpergewicht. Dies korreliert in epidemiologischen Studien mit einer erhöhten Inzidenz und Prävalenz von kardiovaskulären Erkrankungen und ist ein wichtiger Indikator für die Entwicklung des metabolischen Syndroms.

Literatur

  1. 1.
    Longo, D.L., Fauci, A. S., Kasper, D.L., Hauser, S.L. 2011. Harrison´s Principles of Internal Medicine. McGraw-Hill: Professional.Google Scholar
  2. 2.
    James, W.P.T. 1976. Research on obesity. London: Her Majesty´s Stationary Office.Google Scholar
  3. 3.
    Hallynck, T.H., Soep, H.H., Thomis, J.A., Boelaert, J., Daneels, R., Dettli, L. 1981. Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol 11: 523-526.PubMedCrossRefGoogle Scholar
  4. 4.
    Durnin, J.V., Womersley, J. 1974. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32: 77-97.PubMedCrossRefGoogle Scholar
  5. 5.
    Berres, F., Ulmer, H.V., Lamberty, M. 1980. Calculation of total body fat from skinfold thickness by using an age corrected formula. Pflügers Arch 384, Suppl. R35.Google Scholar
  6. 6.
    von Restorff, W. 2004. Leitlinien der Deutschen Gesellschaft für Arbeitsmedizin und Umweltmedizin e.V. (DGAUM). http://www-dgaum.med.uni-rostock.de/leitlinien/fettgehalt.htm.
  7. 7.
    Schaffler, A., Muller-Ladner, U., Scholmerich, J., Buchler, C. 2006. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 27: 449-467.PubMedCrossRefGoogle Scholar
  8. 8.
    Beltowski, J. 2003. Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monitor 9: RA55-61.Google Scholar
  9. 9.
    Bowles, L., Kopelman, P. 2001. Leptin: of mice and men? J Clin Pathol 54: 1-3.PubMedCrossRefGoogle Scholar
  10. 10.
    Caro, J.F., Sinha, M.K., Kolaczynski, J.W., Zhang, P.L., Considine, R.V. 1996. Leptin: the tale of an obesity gene. Diabetes 45: 1455-1462.PubMedGoogle Scholar
  11. 11.
    Chan, J.L., Mantzoros, C.S. 2005. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 366: 74-85.PubMedCrossRefGoogle Scholar
  12. 12.
    Dardeno, T.A., Chou, S.H., Moon, H.S., Chamberland, J.P., Fiorenza, C.G., Mantzoros, C.S. 2010. Leptin in human physiology and therapeutics. Frontiers Neuroendocrinol 31: 377-393.CrossRefGoogle Scholar
  13. 13.
    Kelesidis, T., Mantzoros, C.S. 2006. The emerging role of leptin in humans. Pediatri Endocrinol Rev 3: 239-248.Google Scholar
  14. 14.
    Cui, J., Panse, S., Falkner, B. 2011. The role of adiponectin in metabolic and vascular disease: a review. Clin Nephrol 75: 26-33.PubMedGoogle Scholar
  15. 15.
    Haluzik, M., Parizkova, J., Haluzik, M.M. 2004. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res/Academia Scientiarum Bohemoslovaca 53: 123-129.Google Scholar
  16. 16.
    Han, S.H., Quon, M.J., Kim, J.A., Koh, K.K. 2007. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am College Cardiol 49: 531-538.CrossRefGoogle Scholar
  17. 17.
    Kadowaki, T., Yamauchi, T. 2005. Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451.PubMedCrossRefGoogle Scholar
  18. 18.
    Koerner, A., Kratzsch, J., Kiess, W. 2005. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best practice and research. Clin Endocrinol Metabol 19: 525-546.Google Scholar
  19. 19.
    Haluzik, M., Haluzikova, D. 2006. The role of resistin in obesity-induced insulin resistance. Curr Opin Investig Drugs 7: 306-311.PubMedGoogle Scholar
  20. 20.
    Barnes, K.M., Miner, J.L. 2009. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Peptide Sci 10: 96-107.CrossRefGoogle Scholar
  21. 21.
    Chang, Y.H., Chang, D.M., Lin, K.C., Shin, S.J., Lee, Y.J. 2011. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes/Metabolism Res Rev 27: 515-527.CrossRefGoogle Scholar
  22. 22.
    Sonoli, S.S., Shivprasad, S., Prasad, C.V., Patil, A.B., Desai, P.B., Somannavar, M.S. 2011. Visfatin - a review. Eur Rev Med Pharmacol Sci 15: 9-14.PubMedGoogle Scholar
  23. 23.
    Castaneda, T.R., Tong, J., Datta, R., Culler, M., Tschop, M.H. 2010. Ghrelin in the regulation of body weight and metabolism. Frontiers Neuroendocrinol 31: 44-60.CrossRefGoogle Scholar
  24. 24.
    Al Massadi, O., Tschop, M.H., Tong, J. 2011. Ghrelin acylation and metabolic control. Peptides 32: 2301-2308.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen, C.Y., Asakawa, A., Fujimiya, M., Lee, S.D., Inui, A. 2009. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 61: 430-481.PubMedCrossRefGoogle Scholar
  26. 26.
    Tan, B.K., Adya, R., Randeva, H.S. 2010. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovascular Med 20: 143-148.CrossRefGoogle Scholar
  27. 27.
    Ernst, M.C., Sinal, C.J. 2010. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 21: 660-667.PubMedCrossRefGoogle Scholar
  28. 28.
    Bluher, M. 2011. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 41: 176-182.PubMedCrossRefGoogle Scholar
  29. 29.
    Compton, S.A., Cheatham, B. 2010. CTRP-3: blocking a toll booth to obesity-related inflammation. Endocrinol 151: 5095-5097.CrossRefGoogle Scholar
  30. 30.
    Pfützner, A., Forst, T., Rancier, M., Weryha, G. 2011. Metabolisches Syndrom. Clinical and Technical Review. TECO medical Group. http://teco-medical.ch/downloads/pdf/Diabetes_2009_d_17.pdf: 1-31.
  31. 31.
    El-Mesallamy, H.O., El-Derany, M.O., Hamdy, N.M. 2011. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabetic Med 28: 1194-1200.PubMedCrossRefGoogle Scholar
  32. 32.
    Akbarzadeh, S., Nabipour, I., Jafari, S.M., Movahed, A., Motamed, N., Assadi, M. Hajian, N. 2012. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 95: 132-138.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • A. Schäffler
    • 1
  • C. Bollheimer
    • 1
  • R. Büttner
    • 1
  • C. Girlich
    • 1
  • C. Aslanidis
    • 2
  • W. Dietmaier
    • 3
  • M. Bala
    • 1
  • V. Guralnik
    • 1
  • T. Karrasch
    • 1
  • S. Wurm
    • 1
  1. 1.Klinik und Poliklinik für Innere Medizin IKlinikum der Universität RegensburgRegensburgDeutschland
  2. 2.Institut für Klinische Chemie und LaboratoriumsmedizinKlinikum der Universität RegensburgRegensburgDeutschland
  3. 3.Institut für PathologieKlinikum der Universität RegensburgRegensburgDeutschland

Personalised recommendations